Brief: Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study And Provides Pipeline And Corporate Updates

Vincerx Pharma

07/10/2024 21:27

Vincerx Pharma Inc  VINC.O :
    * VINCERX REPORTS POSITIVE INITIAL CLINICAL DATA FROM
ONGOING
VIP943 PHASE 1 DOSE-ESCALATION STUDY AND PROVIDES PIPELINE AND
CORPORATE UPDATES
    * VINCERX PHARMA INC - EXPECTED CASH RUNWAY INTO EARLY 2025
    * VINCERX PHARMA INC - VINCERX FOCUSING RESOURCES ON
CONTINUED
DEVELOPMENT OF VIP943
    * VINCERX PHARMA INC - VIP943 DEMONSTRATES PROMISING SAFETY
AND
TOLERABILITY AND ACHIEVES TWO COMPLETE RESPONSES TO DATE IN
PHASE 1 DOSE-ESCALATION STUDY
    * VINCERX PHARMA INC - ANTICIPATES PROVIDING ANOTHER DATA
UPDATE
ON ONGOING PHASE 1 VIP943 STUDY BY END OF YEAR.

Source text for Eikon:  ID:nGNX38Dyzc 
Further company coverage:  VINC.O